TrialInternational journal of clinical oncology2014

Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.

Takayuki Ueno et al.PubMed ↗Publisher ↗

No numbers read from the abstract.